We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
Read MoreHide Full Article
Shares of Cencora, Inc. (COR - Free Report) scaled a new 52-week high of $208.70 on Jan 2, 2024, before closing the session marginally lower at $208.54.
Over the past year, this Zacks Rank #2 (Buy) stock has gained 28% against a 2% decline of the industry. The S&P 500 has witnessed 23.8% growth in the said time frame.
Over the past five years, the company registered earnings growth of 13% compared with the industry’s 12.8% rise. The company’s long-term expected growth rate of 8.9% compares with the industry’s growth projection of 13.9%. Cencora’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 3.9%.
Cencora is witnessing an upward trend in its stock price, prompted by its strength in the U.S. Healthcare Solutions business. The optimism led by a solid fourth-quarter fiscal 2023 performance and generics and new product launches are expected to contribute further. However, stiff competition and generic deflation persist.
Image Source: Zacks Investment Research
Let’s delve deeper.
Key Growth Drivers
Generics and New Product Launches: Cencora is expected to benefit from generics growth in the long run, raising investors’ optimism. Cencora is well-positioned to help ensure products get to market as efficiently as possible. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to care, improved economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs, and a continued good brand pricing environment should drive growth. Moreover, the company’s focus on specialty drugs has boded well.
Strength in U.S. Healthcare Solutions Business: The U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. The segment benefits from increasing volume and an expanding customer base, raising investors’ optimism. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, enhanced economic conditions and population demographics are likely to favor the segment in the quarters to come.
In the fiscal fourth quarter of 2023, revenues in this segment reflected a rise of 13% on a year-over-year basis on the back of an increase in specialty product sales coupled with overall market growth.
Strong Q4 Results: Cencora’s impressive fourth-quarter fiscal 2023 results buoy optimism. The company’s strong segmental performance on the back of growth in all markets and strong demand for specialty products, especially GLP-1 drugs, were encouraging. Per management, Cencora delivered a solid performance by playing a crucial role in the healthcare system while maintaining efficiency throughout its business. The company remains focused on its strategic priorities and thoughtful capital deployment to deliver long-term growth.
Downsides
Generic Deflation: Generic deflation has been higher than historic norms for several quarters for Cencora, creating a headwind for the business. Generic deflation is still mid to high single-digits for the company.
Stiff Competition: Cencora operates in a highly competitive pharmaceutical distribution and related healthcare services market. The generic industry is facing consolidation of customers and manufacturers, globalization and increasing quality and regulatory challenges. The company faces additional competition from manufacturers, chain drugstores, specialty distributors and packaging and healthcare technology companies.
Other Key Picks
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 17.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 36.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 38.6% compared with the industry’s 10% rise in the past year.
Merit Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 11.5%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average being 14.4%.
Merit Medical has gained 9.1% compared with the industry’s 12% rise in the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.9%.
Integer Holdings’ shares have rallied 44.7% compared with the industry’s 1.7% rise in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
Shares of Cencora, Inc. (COR - Free Report) scaled a new 52-week high of $208.70 on Jan 2, 2024, before closing the session marginally lower at $208.54.
Over the past year, this Zacks Rank #2 (Buy) stock has gained 28% against a 2% decline of the industry. The S&P 500 has witnessed 23.8% growth in the said time frame.
Over the past five years, the company registered earnings growth of 13% compared with the industry’s 12.8% rise. The company’s long-term expected growth rate of 8.9% compares with the industry’s growth projection of 13.9%. Cencora’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 3.9%.
Cencora is witnessing an upward trend in its stock price, prompted by its strength in the U.S. Healthcare Solutions business. The optimism led by a solid fourth-quarter fiscal 2023 performance and generics and new product launches are expected to contribute further. However, stiff competition and generic deflation persist.
Image Source: Zacks Investment Research
Let’s delve deeper.
Key Growth Drivers
Generics and New Product Launches: Cencora is expected to benefit from generics growth in the long run, raising investors’ optimism. Cencora is well-positioned to help ensure products get to market as efficiently as possible. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to care, improved economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs, and a continued good brand pricing environment should drive growth. Moreover, the company’s focus on specialty drugs has boded well.
Strength in U.S. Healthcare Solutions Business: The U.S. Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable segment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. The segment benefits from increasing volume and an expanding customer base, raising investors’ optimism. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, enhanced economic conditions and population demographics are likely to favor the segment in the quarters to come.
In the fiscal fourth quarter of 2023, revenues in this segment reflected a rise of 13% on a year-over-year basis on the back of an increase in specialty product sales coupled with overall market growth.
Strong Q4 Results: Cencora’s impressive fourth-quarter fiscal 2023 results buoy optimism. The company’s strong segmental performance on the back of growth in all markets and strong demand for specialty products, especially GLP-1 drugs, were encouraging. Per management, Cencora delivered a solid performance by playing a crucial role in the healthcare system while maintaining efficiency throughout its business. The company remains focused on its strategic priorities and thoughtful capital deployment to deliver long-term growth.
Downsides
Generic Deflation: Generic deflation has been higher than historic norms for several quarters for Cencora, creating a headwind for the business. Generic deflation is still mid to high single-digits for the company.
Stiff Competition: Cencora operates in a highly competitive pharmaceutical distribution and related healthcare services market. The generic industry is facing consolidation of customers and manufacturers, globalization and increasing quality and regulatory challenges. The company faces additional competition from manufacturers, chain drugstores, specialty distributors and packaging and healthcare technology companies.
Other Key Picks
A few other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 17.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 36.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 38.6% compared with the industry’s 10% rise in the past year.
Merit Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 11.5%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average being 14.4%.
Merit Medical has gained 9.1% compared with the industry’s 12% rise in the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.9%.
Integer Holdings’ shares have rallied 44.7% compared with the industry’s 1.7% rise in the past year.